Interoceptive regulation of skeletal tissue homeostasis and repair

Wang, X., Xu, J. & Kang, Q. Neuromodulation of bone: role of different peptides and their interactions (Review). Mol. Med. Rep 23, 32 (2021).

Yao, D. et al. Bone metabolism regulation: implications for the treatment of bone diseases. Biomed. Pharmacother. 129, 110494 (2020).

Sharan, K. & Yadav, V. K. Hypothalamic control of bone metabolism. Best. Pr. Res. Clin. Endocrinol. Metab. 28, 713–723 (2014).

Wee, N. K., Kulkarni, R. N., Horsnell, H. & Baldock, P. A. The brain in bone and fuel metabolism. Bone 82, 56–63 (2016).

Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S. & Schwartz, M. W. Central nervous system control of food intake and body weight. Nature 443, 289–295 (2006).

Karsenty, G. & Khosla, S. The crosstalk between bone remodeling and energy metabolism: a translational perspective. Cell Metab. 34, 805–817 (2022).

Corr, A., Smith, J. & Baldock, P. Neuronal control of bone remodeling. Toxicol. Pathol. 45, 894–903 (2017).

Driessler, F. & Baldock, P. A. Hypothalamic regulation of bone. J. Mol. Endocrinol. 45, 175–181 (2010).

Elefteriou, F. Impact of the autonomic nervous system on the skeleton. Physiol. Rev. 98, 1083–1112 (2018).

Brazill, J. M., Beeve, A. T., Craft, C. S., Ivanusic, J. J. & Scheller, E. L. Nerves in bone: evolving concepts in pain and anabolism. J. Bone Min. Res. 34, 1393–1406 (2019).

Wang, X. D. et al. The neural system regulates bone homeostasis via mesenchymal stem cells: a translational approach. Theranostics 10, 4839–4850 (2020).

Xu, J. et al. The effects of calcitonin gene-related peptide on bone homeostasis and regeneration. Curr. Osteoporos. Rep. 18, 621–632 (2020).

Li, F. X. et al. The role of substance p in the regulation of bone and cartilage metabolic activity. Front. Endocrinol. (Lausanne) 11, 77 (2020).

Kawai, M., Kinoshita, S., Shimba, S., Ozono, K. & Michigami, T. Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. J. Biol. Chem. 289, 1457–1466 (2014).

Takeda, S. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111, 305–317 (2002).

Lv, X., Gao, F. & Cao, X. Skeletal interoception in bone homeostasis and pain. Cell Metab. 34, 1914–1931 (2022).

Xia, Z. Skeletal interoception: an emerging area for musculoskeletal research. Biomater. Transl. 3, 237–239 (2022).

Zhen, G. & Cao, X. Targeting TGF beta signaling in subchondral bone and articular cartilage homeostasis. Trends Pharmacol. Sci. 35, 227–236 (2014).

Bian, Q. et al. Excessive activation of TGF beta by spinal instability causes vertebral endplate sclerosis. Sci. Rep 6, 27093 (2016).

Zhu, J. et al. Aberrant subchondral osteoblastic metabolism modifies Na-v 1.8 for osteoarthritis. Elife 9, e57656 (2020).

Tozzi, A. Information processing in the CNS: a supramolecular chemistry. Cogn. Neurodyn. 9, 463–477 (2015).

Petty, S. J., Wilding, H. & Wark, J. D. Osteoporosis associated with epilepsy and the use of anti-epileptics-a review. Curr. Osteoporos. Rep. 14, 54–65 (2016).

Kishimoto, T., De Hert, M., Carlson, H. E., Manu, P. & Correll, C. U. Osteoporosis and fracture risk in people with schizophrenia. Curr. Opin. Psychiatry 25, 415–429 (2012).

Huang, W.-S. et al. Post-traumatic stress disorder and risk of osteoporosis: a nationwide longitudinal study. Stress Health 34, 440–445 (2018).

Aloumanis, K. & Mavroudis, K. The “depressive” face of osteoporosis and the “osteoporotic” face of depression. Hormones-Int. J. Endocrinol. Metab. 12, 350–362 (2013).

Carda, S., Cisari, C., Invernizzi, M. & Bevilacqua, M. Osteoporosis after stroke: a review of the causes and potential treatments. Cerebrovasc. Dis. 28, 191–200 (2009).

Chen, Y.-H. & Lo, R. Y. Alzheimer’s disease and osteoporosis. Tzu-chi Med. J. 29, 138–142 (2017).

Ezzatian-Ahar, S., Schwarz, P. & Pedersen, S. W. Osteoporosis often occurs in Parkinson’s disease patients. Ugeskrift for laeger 176, 36 (2014).

Takenouchi, T., Sato, W., Torii, C. & Kosaki, K. Progressive cognitive decline in an adult patient with cleidocranial dysplasia. Eur. J. Med. Genet. 57, 319–321 (2014).

Otto, E. et al. Crosstalk of brain and bone-clinical observations and their molecular bases. Int. J. Mol. Sci. 21, 4946 (2020).

Yang, C. et al. The effect of traumatic brain injury on bone healing from a novel exosome centered perspective in a mice model. J. Orthop. Transl. 30, 70–81 (2021).

Bajwa, N. M., Kesavan, C. & Mohan, S. Long-term consequences of traumatic brain injury in bone metabolism. Front. Neurol. 9, 115 (2018).

McDonald, S. J., Sun, M., Agoston, D. V. & Shultz, S. R. The effect of concomitant peripheral injury on traumatic brain injury pathobiology and outcome. J. Neuroinflammation 13, 90 (2016).

Sullivan, M. P., Torres, S. J., Mehta, S. & Ahn, J. Heterotopic ossification after central nervous system trauma: a current review. Bone Jt. Res. 2, 51–57 (2013).

Ducy, P. et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100, 197–207 (2000).

Abeynayake, N., Arthur, A. & Gronthos, S. Crosstalk between skeletal and neural tissues is critical for skeletal health. Bone 142, 115645 (2021).

Dimitri, P. & Rosen, C. The central nervous system and bone metabolism: an evolving story. Calcif. Tissue Int. 100, 476–485 (2017).

Ma, Q. A functional subdivision within the somatosensory system and its implications for pain research. Neuron 110, 749–769 (2022).

Wang, K. et al. Single-cell transcriptomic analysis of somatosensory neurons uncovers temporal development of neuropathic pain. Cell Res. 31, 904–918 (2021).

Chen, W. G. et al. The emerging science of interoception: sensing, integrating, interpreting, and regulating signals within the self. Trends Neurosci. 44, 3–16 (2021).

Quadt, L., Critchley, H. D. & Garfinkel, S. N. The neurobiology of interoception in health and disease. Ann. N. Y. Acad. Sci. 1428, 112–128 (2018).

Proske, U. & Gandevia, S. C. The proprioceptive senses: their roles in signaling body shape, body position and movement, and muscle force. Physiol. Rev. 92, 1651–1697 (2012).

Jones, L. A. & Smith, A. M. Tactile sensory system: encoding from the periphery to the cortex. Wiley Interdiscip. Rev. Syst. Biol. Med. 6, 279–287 (2014).

Tomlinson, R. E., Christiansen, B. A., Giannone, A. A. & Genetos, D. C. The role of nerves in skeletal development, adaptation, and aging. Front. Endocrinol. (Lausanne) 11, 646 (2020).

Matsuo, K. et al. Innervation of the tibial epiphysis through the intercondylar foramen. Bone 120, 297–304 (2019).

Castaneda-Corral, G. et al. The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience 178, 196–207 (2011).

Jimenez-Andrade, J. M. et al. A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain. Bone 46, 306–313 (2010).

Mantyh, P. W. The neurobiology of skeletal pain. Eur. J. Neurosci. 39, 508–519 (2014).

Yoneda, T., Hiasa, M., Okui, T. & Hata, K. Sensory nerves: a driver of the vicious cycle in bone metastasis? J. Bone Oncol. 30, 100387 (2021).

Martin, C. D., Jimenez-Andrade, J. M., Ghilardi, J. R. & Mantyh, P. W. Organization of a unique net-like meshwork of CGIZP plus sensory fibers in the mouse periosteum: implications for the generation and maintenance of bone fracture pain. Neurosci. Lett. 427, 148–152 (2007).

Pongratz, G. & Straub, R. H. Role of peripheral nerve fibres in acute and chronic inflammation in arthritis. Nat. Rev. Rheumatol. 9, 117–126 (2013).

Nencini, S. et al. Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain. Molecular Pain 13, 1744806917697011 (2017).

Tomlinson, R. E. et al. NGF-TrkA signaling by sensory nerves coordinates the vascularization and ossification of developing endochondral bone. Cell Rep. 16, 2723–2735 (2016).

Sayilekshmy, M. et al. Innervation is higher above bone remodeling surfaces and in cortical pores in human bone: lessons from patients with primary hyperparathyroidism. Sci. Rep. 9, 5361 (2019).

Chen, H. et al. Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis. Nat. Commun. 10, 181 (2019).

Hu, B. et al. Sensory nerves regulate mesenchymal stromal cell lineage commitment by tuning sympathetic tones. J. Clin. Invest. 130, 3483–3498 (2020).

Trudeau, J. et al. Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13. J. Allergy Clin. Immunol. 117, 1446–1454 (2006).

Lanza, F. L., Chan, F. K. & Quigley, E. M. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 104, 728–738 (2009).

Richards, J. B. et al. The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study. Osteoporos. Int. 17, 1410–1419 (2006).

Dimmen, S., Nordsletten, L., Engebretsen, L., Steen, H. & Madsen, J. E. Negative effect of parecoxib on bone mineral during fracture healing in rats. Acta orthopaedica 79, 438–444 (2008).

Weinreb, M., Suponitzky, I. & Keila, S. Systemic administration of an anabolic dose of PGE(2) in young rats increases the osteogenic capacity of bone marrow. Bone 20, 521–526 (1997).

Park, J., Fertala, A. & Tomlinson, R. E. Naproxen impairs load-induced bone formation, reduces bone toughness, and diminishes woven bone formation following stress fracture in mice. Bone 124, 22–32 (2019).

Roizen, J. D., Asada, M., Tong, M., Tai, H. H. & Muglia, L. J. Early pregnancy loss in 15-hydroxyprostaglandin dehydrogenase knockout (15-HPGD^-/-) mice due to requirement for embryo 15-HPGD activity. Sci. Rep. 9, 17612 (2019).

Lu, Q. et al. Clinical and biochemical characteristics of 12 Chinese primary hypertrophic osteoarthropathy patients with HPGD mutations. Int. J. Biol. Sci. 18, 3908–3917 (2022).

Tomlinson, R. E. et al. NGF-TrkA signaling in sensory nerves is required for skeletal adaptation to mechanical loads in mice. Proc. Natl. Acad. Sci. USA. 114, E3632–e3641 (2017).

Eimar, H. et al. Donepezil regulates energy metabolism and favors bone mass accrual. Bone 84, 131–138 (2016).

Parkman, H. P. & Jones, M. P. Tests of gastric neuromuscular function. Gastroenterology 136, 1526–1543 (2009).

Chenu, C. Role of innervation in the control of bone remodeling. J. Musculoskelet. Neuronal Interact. 4, 132–134 (2004).

Oury, F. et al. CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev. 24, 2330–2342 (2010).

Riddle, R. C. & Clemens, T. L. Bone cell bioenergetics and skeletal energy homeostasis. Physiol. Rev. 97, 667–698 (2017).

Zhang, Q., Riddle, R. C. & Clemens, T. L. Bone and the regulation of global energy balance. J. Intern. Med. 277, 681–689 (2015).

Perez-Lopez, L. M., Cabrera-Gonzalez, M., Gutierrez-de la Iglesia, D., Ricart, S. & Knorr-Gimenez, G. Update review and clinical presentation in congenital insensitivity to pain and anhidrosis. Case Rep. pediatrics 2015, 589852 (2015).

Nahar, N., Mohamed, S., Mustapha, N. M. & Fong, L. S. Protective effects of Labisia pumila against neuropathy in a diabetic rat model. J. Diabetes Metab. Disord. 21, 1–11 (2022).

Zhang, Y. et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science 348, aaa2340 (2015).

Yoshida, K. et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc. Natl. Acad. Sci. USA 99, 4580–4585 (2002).

Cherruau, M., Morvan, F. O., Schirar, A. & Saffar, J. L. Chemical sympathectomy-induced changes in TH-, VIP-, and CGRP-immunoreactive fibers in the rat mandible periosteum: influence on bone resorption. J. Cell Physiol. 194, 341–348 (2003).

Agostoni, E., Chinnock, J. E., De Daly, M. B. & Murray, J. G. Functional and histological studies of the vagus nerve and its branches to the heart, lungs and abdominal viscera in the cat. J. Physiol. 135, 182–205 (1957).

Catala, M. & Kubis, N. Gross anatomy and development of the peripheral nervous system. Handb. Clin. Neurol. 115, 29–41 (2013).

Imai, S., Tokunaga, Y., Maeda, T., Kikkawa, M. & Hukuda, S. Calcitonin gene-related peptide, substance P, and tyrosine hydroxylase-immunoreactive innervation of rat bone marrows: an immunohistochemical and ultrastructural investigation on possible efferent and afferent mechanisms. J. Orthop. Res. 15, 133–140 (1997).

Ivanusic, J. J. Size, neurochemistry, and segmental distribution of sensory neurons innervating the rat tibia. J. Comp. Neurol. 517, 276–283 (2009).

Duncan, C. P. & Shim, S. S. J. Edouard Samson Address: the autonomic nerve supply of bone. An experimental study of the intraosseous adrenergic nervi vasorum in the rabbit. J. Bone Jt. Surg. Br. 59, 323–330 (1977).

Yirmiya, R. et al. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc. Natl. Acad. Sci. USA. 103, 16876–16881 (2006).

Hill, E. L. & Elde, R. Distribution of CGRP-, VIP-, D beta H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 264, 469–480 (1991).

Kajimura, D., Paone, R., Mann, J. J. & Karsenty, G. Foxo1 regulates Dbh expression and the activity of the sympathetic nervous system in vivo. Mol. Metab. 3, 770–777 (2014).

Ahmed, M., Bjurholm, A., Kreicbergs, A. & Schultzberg, M. Neuropeptide Y, tyrosine hydroxylase and vasoactive intestinal polypeptide-immunoreactive nerve fibers in the vertebral bodies, discs, dura mater, and spinal ligaments of the rat lumbar spine. Spine (Philos. Pa 1976) 18, 268–273 (1993).

Ma, Y. et al. Extracellular norepinephrine clearance by the norepinephrine transporter is required for skeletal homeostasis. J. Biol. Chem. 288, 30105–30113 (2013).

Aitken, S. J., Landao-Bassonga, E., Ralston, S. H. & Idris, A. I. Beta2-adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Arch. Biochem. Biophys. 482, 96–103 (2009).

Lundberg, J. M., Hökfelt, T., Fahrenkrug, J., Nilsson, G. & Terenius, L. Peptides in the cat carotid body (glomus caroticum): VIP-, enkephalin-, and substance P-like immunoreactivity. Acta Physiol. Scand. 107, 279–281 (1979).

Lundberg, P. et al. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: Presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. Endocrinology 142, 339–347 (2001).

Bajayo, A. et al. Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc. Natl. Acad. Sci. USA. 109, 15455–15460 (2012).

En-Nosse, M. et al. Expression of non-neuronal cholinergic system in osteoblast-like cells and its involvement in osteogenesis. Cell Tissue Res. 338, 203–215 (2009).

Bellido, T. Osteocyte-driven bone remodeling. Calcif. Tissue Int. 94, 25–34 (2014).

Klein-Nulend, J. et al. Sensitivity of osteocytes to biomechanical stress in vitro. Faseb J. 9, 441–445 (1995).

Han, J. et al. DNA synthesis of rat bone marrow mesenchymal stem cells through alpha1-adrenergic receptors. Arch. Biochem. Biophys. 490, 96–102 (2009).

Ma, Y. et al. β2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of glucocorticoids on bone. Endocrinology 152, 1412–1422 (2011).

Moore, R. E., Smith, C. K. 2nd, Bailey, C. S., Voelkel, E. F. & Tashjian, A. H. Jr. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Min. 23, 301–315 (1993).

Fonseca, T. L. et al. Double disruption of α2A- and α2C-adrenoceptors results in sympathetic hyperactivity and high-bone-mass phenotype. J. Bone Min. Res. 26, 591–603 (2011).

Elefteriou, F. Regulation of bone remodeling by the central and peripheral nervous system. Arch. Biochem. Biophys. 473, 231–236 (2008).

Togari, A. et al. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci. Lett. 233, 125–128 (1997).

Bonnet, N. et al. Combined effects of exercise and propranolol on bone tissue in ovariectomized rats. J. Bone Min. Res. 22, 578–588 (2007).

Pierroz, D. D., Bouxsein, M. L., Rizzoli, R. & Ferrari, S. L. Combined treatment with a beta-blocker and intermittent PTH improves. Bone mass Microarchitecture ovariectomized mice. Bone 39, 260–267 (2006).

Swift, J. M., Hogan, H. A. & Bloomfield, S. A. β-1 adrenergic agonist mitigates unloading-induced bone loss by maintaining formation. Med. Sci. Sports Exerc. 45, 1665–1673 (2013).

Swift, J. M., Swift, S. N., Allen, M. R. & Bloomfield, S. A. Beta-1 adrenergic agonist treatment mitigates negative changes in cancellous bone microarchitecture and inhibits osteocyte apoptosis during disuse. PLoS One 9, e106904 (2014).

Elefteriou, F. et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434, 514–520 (2005).

Bouxsein, M. L. et al. Mice lacking beta-adrenergic receptors have increased bone mass but are not protected from deleterious skeletal effects of ovariectomy. Endocrinology 150, 144–152 (2009).

Pierroz, D. D. et al. Deletion of β-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation. J. Bone Min. Res. 27, 1252–1262 (2012).

Khosla, S. et al. Sympathetic β1-adrenergic signaling contributes to regulation of human bone metabolism. J. Clin. Invest. 128, 4832–4842 (2018).

Fu, L., Patel, M. S. & Karsenty, G. The circadian modulation of leptin-controlled bone formation. Prog. Brain Res. 153, 177–188 (2006).

Wu, Y., Zhang, Q., Zhao, B. & Wang, X. Effect and mechanism of propranolol on promoting osteogenic differentiation and early implant osseointegration. Int. J. Mol. Med. 48, 191 (2021).

Pierce, J. L. et al. The glucocorticoid receptor in osteoprogenitors regulates bone mass and marrow fat. J. Endocrinol. 243, 27–42 (2019).

Wang, Z. et al. Mechanical loading alleviated the inhibition of β2-adrenergic receptor agonist terbutaline on bone regeneration. Faseb J. 35, e22033 (2021).

Minkowitz, B., Boskey, A. L., Lane, J. M., Pearlman, H. S. & Vigorita, V. J. Effects of propranolol on bone metabolism in the rat. J. Orthop. Res. 9, 869–875 (1991).

Niedermair, T. et al. Absence of substance P and the sympathetic nervous system impact on bone structure and chondrocyte differentiation in an adult model of endochondral ossification. Matrix Biol. 38, 22–35 (2014).

Gadomski, S. et al. A cholinergic neuroskeletal interface promotes bone formation during postnatal growth and exercise. Cell Stem Cell 29, 528–544.e529 (2022).

Loi, F. et al. Inflammation, fracture and bone repair. Bone 86, 119–130 (2016).

Ibeas, K., Herrero, L., Mera, P. & Serra, D. Hypothalamus-skeletal muscle crosstalk during exercise and its role in metabolism modulation. Biochem. Pharm. 190, 114640 (2021).

Liu, T., Xu, Y., Yi, C. X., Tong, Q. & Cai, D. The hypothalamus for whole-body physiology: from metabolism to aging. Protein Cell 13, 394–421 (2022).

Rexach, J. E. et al. Dynamic O-GlcNAc modification regulates CREB-mediated gene expression and memory formation. Nat. Chem. Biol. 8, 253–261 (2012).

Xue, P. et al. PGE2/EP4 skeleton interoception activity reduces vertebral endplate porosity and spinal pain with low-dose celecoxib. Bone Res. 9, 36 (2021).

Both, T. et al. Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J. Cell. Mol. Med. 22, 873–882 (2018).

Wang, S. et al. Exosomes secreted by mesenchymal stromal/stem cell-derived adipocytes promote breast cancer cell growth via activation of Hippo signaling pathway. Stem cell Res. Ther. 10, 117 (2019).

Reesink, H. L. et al. Galectin-1 and galectin-3 expression in equine mesenchymal stromal cells (MSCs), synovial fibroblasts and chondrocytes, and the effect of inflammation on MSC motility. Stem Cell Res. Ther. 8, 243 (2017).

Bozorgmehr, M. et al. Endometrial and menstrual blood mesenchymal stem/stromal cells: biological properties and clinical application. Front. Cell Developmental Biol. 8, 497 (2020).

Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994).

Friedman, J. 20 years of leptin: leptin at 20: an overview. J. Endocrinol. 223, T1–T8 (2014).

Baldock, P. A. et al. Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J. Bone Min. Res. 21, 1600–1607 (2006).

Steppan, C. M., Crawford, D. T., Chidsey-Frink, K. L., Ke, H. Z. & Swick, A. G. Leptin is a potent stimulator of bone growth in ob/ob mice. Regulatory Pept. 92, 73–78 (2000).

Takeshita, N., Mutoh, S. & Yamaguchi, I. Osteopenia in genetically diabetic DB/DB mice and effects of 1alpha-hydroxyvitamin D3 on the osteopenia. Basic Research Group. Life Sci. 56, 1095–1101 (1995).

Hamrick, M. W., Pennington, C., Newton, D., Xie, D. & Isales, C. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34, 376–383 (2004).

Parker, R. M. & Herzog, H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur. J. Neurosci. 11, 1431–1448 (1999).

Sun, J. S. et al. Ventromedial hypothalamic primary cilia control energy and skeletal homeostasis. J. Clin. Investig. 131, e138107 (2021).

Yadav, V. K. et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138, 976–989 (2009).

Yadav, V. K. et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135, 825–837 (2008).

Upadhyay, J., Farr, O. M. & Mantzoros, C. S. The role of leptin in regulating bone metabolism. Metabolism 64, 105–113 (2015).

Turner, R. T. et al. Peripheral leptin regulates bone formation. J. Bone Miner. Res. 28, 22–34 (2013).

Philbrick, K. A. et al. Effects of hypothalamic leptin gene therapy on osteopetrosis in leptin-deficient mice. J. Endocrinol. 236, 57–68 (2018).

Tsuji, K., Maeda, T., Kawane, T., Matsunuma, A. & Horiuchi, N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J. Bone Min. Res. 25, 1711–1723 (2010).

Wu, Z., Shao, P., Dass, C. R. & Wei, Y. Systemic leptin administration alters callus VEGF levels and enhances bone fracture healing in wildtype and ob/ob mice. Injury 49, 1739–1745 (2018).

Liu, X. et al. Decrease in leptin mediates rat bone metabolism impairments during high-fat diet-induced catch-up growth by modulating the OPG/RANKL balance. 3 Biotech 11, 103 (2021).

Zhang, B. et al. Leptin potentiates BMP9-induced osteogenic differentiation of mesenchymal stem cells through the activation of JAK/STAT signaling. Stem Cells Dev. 29, 498–510 (2020).

Ruiz-Heiland, G., Yong, J. W., von Bremen, J. & Ruf, S. Leptin reduces in vitro cementoblast mineralization and survival as well as induces PGE2 release by ERK1/2 commitment. Clin. Oral. Investig. 25, 1933–1944 (2021).

Lee, N. J. & Herzog, H. NPY regulation of bone remodelling. Neuropeptides 43, 457–463 (2009).

Chen, Q. C. & Zhang, Y. The role of NPY in the regulation of bone metabolism. Front. Endocrinol. (Lausanne) 13, 833485 (2022).

Clemenzi, M. N. et al. Analysis of western diet, palmitate and BMAL1 regulation of neuropeptide Y expression in the murine hypothalamus and BMAL1 knockout cell models. Mol. Cell. Endocrinol. 507, 110773 (2020).

Wu, J.-Q., Jiang, N. & Yu, B. Mechanisms of action of neuropeptide Y on stem cells and its potential applications in orthopaedic disorders. World J. Stem Cells 12, 986–1000 (2020).

Apel, P. J. et al. Effect of selective sensory denervation on fracture-healing an experimental study of rats. J. Bone Jt. Surg.-Am. 91A, 2886–2895 (2009).

Baldock, P. A. et al. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One 4, e8415 (2009).

Allison, S. J. et al. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J. Bone Miner. Res. 24, 294–304 (2009).

Lee, N. J. et al. Osteoblast specific Y1 receptor deletion enhances bone mass. Bone 48, 461–467 (2011).

Baldock, P. A. et al. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Investig. 109, 915–921 (2002).

Matic, I. et al. Bone-specific overexpression of NPY modulates osteogenesis. J. Musculoskelet. Neuronal Interact. 12, 209–218 (2012).

Zhang, Y. et al. Neuronal induction of bone-fat imbalance through osteocyte neuropeptide. Y. Adv. Sci. 8, e2100808 (2021).

Czarnecka, M. et al. Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides 73, 11–24 (2019).

Horsnell, H. & Baldock, P. A. Osteoblastic actions of the neuropeptide Y system to regulate bone and energy homeostasis. Curr. Osteoporos. Rep. 14, 26–31 (2016).

Rethnam, S., Raju, B., Fristad, I., Berggreen, E. & Heyeraas, K. J. Differential expression of neuropeptide Y Y1 receptors during pulpal inflammation. Int. Endod. J. 43, 492–498 (2010).

Wu, W. et al. NPY promotes macrophage migration by upregulating matrix metalloproteinase-8 expression. J. Cell. Physiol. 236, 1903–1912 (2021).

Huang, S. et al. Neural regulation of bone remodeling: Identifying novel neural molecules and pathways between brain and bone. J. Cell Physiol. 234, 5466–5477 (2019).

Sousa, D. M. et al. Ablation of Y-1 receptor impairs osteoclast bone-resorbing activity. Sci. Rep. 6, 33470 (2016).

Sousa, D. M. et al. Neuropeptide Y Y1 receptor antagonism increases bone mass in mice. Bone 51, 8–16 (2012).

Lee, N. J. et al. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J. Bone Miner. Res. 25, 1736–1747 (2010).

Baldock, P. A. et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J. Biol. Chem. 282, 19092–19102 (2007).

Cevik, M. O., Korkusuz, P. & Korkusuz, F. Neuropeptide Y1 receptor antagonist but not neuropeptide Y itself increased bone mineral density when locally injected with hyaluronic acid in male Wistar rats. Turk. J. Med Sci. 50, 1454–1460 (2020).

Sousa, D. M. et al. The lack of neuropeptide Y-Y1 receptor signaling modulates the chemical and mechanical properties of bone matrix. FASEB J. 34, 4163–4177 (2020).

Xie, W. et al. Neuropeptide Y1 receptor antagonist promotes osteoporosis and microdamage repair and enhances osteogenic differentiation of bone marrow stem cells via cAMP/PKA/CREB pathway. Aging-Us 12, 8120–8136 (2020).

Xie, W. et al. Neuropeptide Y1 receptor antagonist alters gut microbiota and alleviates the ovariectomy-induced osteoporosis in rats. Calcif. Tissue Int. 106, 444–454 (2020).

Shi, Y.-C et al. Peripheral-specific Y2 receptor knockdown protects mice from high-fat diet-induced obesity. Obesity 19, 2137–2148 (2011).

Lundberg, P. et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J. Biol. Chem. 282, 19082–19091 (2007).

Allison, S. J. et al. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J. Biol. Chem. 281, 23436–23444 (2006).

Seldeen, K. L. et al. Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density. Neuropeptides 67, 45–55 (2018).

Sainsbury, A. et al. Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol. Cell. Biol. 23, 5225–5233 (2003).

Khor, E.-C. et al. The y6 receptor suppresses bone resorption and stimulates bone formation in mice via a suprachiasmatic nucleus relay. Bone 84, 139–147 (2016).

Wu, J. et al. Neuropeptide Y enhances proliferation and prevents apoptosis in rat bone marrow stromal cells in association with activation of the Wnt/beta-catenin pathway in vitro. Stem Cell Res. 21, 74–84 (2017).

Movafagh, S., Hobson, J. P., Spiegel, S., Kleinman, H. K. & Zukowska, Z. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. Faseb J. 20, 1924 (2006).

Ollmann, M. M. et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. (N. Y.) 278, 135–138 (1997).

Graham, M., Shutter, J. R., Sarmiento, U., Sarosi, I. & Stark, K. L. Overexpression of Agrt leads to obesity in transgenic mice. Nat. Genet. 17, 273–274 (1997).

Ross, A. W. et al. Divergent regulation of hypothalamic neuropeptide Y and agouti-related protein by photoperiod in F344 rats with differential food intake and growth. J. Neuroendocrinol. 21, 610–619 (2009).

Park, S., Peng, X. D., Frohman, L. A. & Kineman, R. D. Expression analysis of hypothalamic and pituitary components of the growth hormone axis in fasted and streptozotocin-treated neuropeptide Y (NPY)-intact (NPY^+/+) and NPY-knockout (NPY^-/-) mice. Neuroendocrinology 81, 360–371 (2005).

Kim, J. G. et al. AgRP neurons regulate bone mass. Cell Rep. 13, 8–14 (2015).

Enriquez, R. F., Lee, N. J. & Herzog, H. AgRP signalling negatively regulates bone mass. J. Neuroendocrinol. 33, e12978 (2021).

Yosten, G. L. C. et al. Past, present and future of cocaine- and amphetamine-regulated transcript peptide. Physiol. Behav. 235, 113380 (2021).

Kristensen, P. et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393, 72–76 (1998).

Ahn, J. D. et al. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 147, 3196–3202 (2006).

Saponaro, F. et al. The role of cannabinoids in bone metabolism: a new perspective for bone disorders. Int. J. Mol. Sci. 22, 12374 (2021).

Basavarajappa, B. S. Critical enzymes involved in endocannabinoid metabolism. Protein Pept. Lett. 14, 237–246 (2007).

Apostu, D. et al. Cannabinoids and bone regeneration. Drug Metab. Rev. 51, 65–75 (2019).

Bab, I., Zimmer, A. & Melamed, E. Cannabinoids and the skeleton: From marijuana to reversal of bone loss. Ann. Med. 41, 560–567 (2009).

Idris, A. I. & Ralston, S. H. Role of cannabinoids in the regulation of bone remodeling. Front. Endocrinol. 3, 136–136 (2012).

Ofek, O. et al. CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J. Bone Miner. Res. 26, 308–316 (2011).

Raphael-Mizrahi, B. & Gabet, Y. The cannabinoids effect on bone formation and bone healing. Curr. Osteoporos. Rep. 18, 433–438 (2020).

Smith, E., Comiskey, C. & Carroll, A. Prevalence of and risk factors for osteoporosis in adults with acquired brain injury. Ir. J. Med. Sci. 185, 473–481 (2016).

Banham-Hall, N., Kothwal, K., Pipkin, J., Bentley, J. & Dickens, G. L. Prevalence of low bone mineral density in inpatients with traumatic brain injury receiving neurobehavioural rehabilitation: a postoperative, observational study. Physiotherapy 99, 328–334 (2013).

Beaupre, G. S. & Lew, H. L. Bone-density changes after stroke. Am. J. Phys. Med. Rehab. 85, 464–472 (2006).

Smith, E. M., Comiskey, C. M. & Carroll, A. M. A study of bone mineral density in adults with disability. Arch. Phys. Med. Rehab. 90, 1127–1135 (2009).

Oppl, B. et al. Low bone mineral density and fragility fractures in permanent vegetative state patients. J. Bone Miner. Res. 29, 1096–1100 (2014).

Yu, H., Watt, H. & Mohan, S. The negative impact of traumatic brain injury (TBI) on bone in a mouse model. Brain Inj. 28, 244–251 (2014).

Yu, H., Wergedal, J. E., Rundle, C. H. & Mohan, S. Reduced bone mass accrual in mouse model of repetitive mild traumatic brain injury. J. Rehab. Res. Dev. 51, 1427–1437 (2014).

Brady, R. D. et al. Experimental traumatic brain injury induces bone loss in rats. J. Neurotrauma 33, 2154–2160 (2016).

McDonald, S. J. et al. Beyond the brain: peripheral interactions after traumatic brain injury. J. Neurotrauma 37, 770–781 (2020).

Rubin, M. R. & Bilezikian, J. P. Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Arquivos Brasileiros De. Endocrinologia E. Metabologia 54, 220–226 (2010).

Ruohola, J.-P. et al. Association between serum 25(OH)D concentrations and bone stress fractures in Finnish young men. J. Bone Miner. Res. 21, 1483–1488 (2006).

Davey, T. et al. Low serum 25-hydroxyvitamin D is associated with increased risk of stress fracture during Royal Marine recruit training. Osteoporos. Int. 27, 171–179 (2016).

Anthonissen, J., Steffen, C. T., Hofmann, A. & Victor, J. The pathogenesis of heterotopic ossification after traumatic brain injury. A review of current literature. Acta Orthopaedica Belgica 86, 369–377 (2020).

Locher, R. J. et al. Traumatic brain injury and bone healing: radiographic and biomechanical analyses of bone formation and stability in a combined murine trauma model. J. Musculoskelet. Neuronal Interact. 15, 309–315 (2015).

Brady, R. D. et al. Closed head experimental traumatic brain injury increases size and bone volume of callus in mice with concomitant tibial fracture. Sci. Rep. 6, 34491 (2016).

Wei, Y., Wang, L., Clark, J. C. M., Dass, C. R. & Choong, P. F. M. Elevated leptin expression in a rat model of fracture and traumatic brain injury. J. Pharm. Pharmacol. 60, 1667–1672 (2008).

Wang, L. et al. Effect of leptin on bone metabolism in rat model of traumatic brain injury and femoral fracture. Chin. J. Traumatol. 14, 7–13 (2011).

Yan, H. et al. Leptin’s effect on accelerated fracture healing after traumatic brain injury. Neurol. Res. 35, 537–544 (2013).

Gu, X. C., Zhang, X. B., Hu, B., Zi, Y. & Li, M. Neuropeptide Y accelerates post-fracture bone healing by promoting osteogenesis of mesenchymal stem cells. Neuropeptides 60, 61–66 (2016).

Tam, J. et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. Faseb J. 22, 285–294 (2008).

Morioka, K. et al. Differential fracture response to traumatic brain injury suggests dominance of neuroinflammatory response in polytrauma. Sci. Rep. 9, 12199 (2019).

Guo, G. et al. Long non-coding RNAs in traumatic brain injury accelerated fracture healing. Front. Surg. 8, 663377 (2021).

Mollahosseini, M., Ahmadirad, H., Goujani, R. & Khorramdelazad, H. The association between traumatic brain injury and accelerated fracture healing: a study on the effects of growth factors and cytokines. J. Mol. Neurosci. 71, 162–168 (2021).

Han, Z. et al. Relationship between miRNA-433 and SPP1 in the presence of fracture and traumatic brain injury. Exp. Ther. Med. 22, 928 (2021).

Hu, L. et al. miRNA-92a-3p regulates osteoblast differentiation in patients with concomitant limb fractures and TBI via IBSP/PI3K-AKT inhibition. Mol. Ther. Nucleic Acids 23, 1345–1359 (2021).

Sun, Y. et al. Downregulation of microRNA-16-5p accelerates fracture healing by promoting proliferation and inhibiting apoptosis of osteoblasts in patients with traumatic brain injury. Am. J. Transl. Res. 11, 4746–4760 (2019).

Xiong, Y. et al. miRNA-26a-5p Accelerates Healing via Downregulation of PTEN in Fracture Patients with Traumatic Brain Injury. Mol. Ther. Nucleic Acids 17, 223–234 (2019).

Zhang, R., Liang, Y. & Wei, S. The expressions of NGF and VEGF in the fracture tissues are closely associated with accelerated clavicle fracture healing in patients with traumatic brain injury. Ther. Clin. Risk Manag 14, 2315–2322 (2018).

Zhang, R., Liang, Y. & Wei, S. M2 macrophages are closely associated with accelerated clavicle fracture healing in patients with traumatic brain injury: a retrospective cohort study. J. Orthop. Surg. Res. 13, 213 (2018).

Zhuang, Y. F. & Li, J. Serum EGF and NGF levels of patients with brain injury and limb fracture. Asian Pac. J. Tropical Med. 6, 383–386 (2013).

Huang, W., Li, Z., Li, Z. & Yang, R. Does traumatic brain injury result in accelerated mandibular fracture healing? J. Oral. Maxillofac. Surg. 70, 2135–2142 (2012).